View Clinical Trial (Medical Research Study)

Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI - NCT00539253-21287(Clinical Trial 186917)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Baltimore
State:  
MD
Zip Code: 21287
Conditions: Hepatocellular Carcinoma
Purpose: This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE). MultiHance is approved by the Food and Drug Administration (FDA) for use as a contrast material for Magnetic Resonance Imaging (MRI) scans of the central nervous system. It is believed that using MultiHance may be able to help doctors tell normal liver cells apart from active tumor and from tumor affected by the chemotherapy. In this way, MultiHance may improve the way patients with hepatocellular carcinoma are managed clinically. We hypothesize that the Multi-Hance contrast material will provide better image definition of treated liver tumor(s) on MRI imaging in comparison to other commercially available contrast agents.
Study summary:
Criteria: Inclusion Criteria: - Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional radiology clinic who are scheduled for TACE. - INR<1.4 - Platelet count > 80,000 Exclusion Criteria: - Contraindications to TACE procedure - Unable to have an MRI Scan - Allergy or hypersensitivity reactions to gadolinium or any other ingredients, including benzyl alcohol - Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias - Known clinical hypersensitivity or a history of asthma or allergic respiratory disorders - Patients with advanced renal failure (those currently requiring dialysis or with a Glomerular Filtration Rate<15cc/min) - Pregnancy
Study is available at: The Johns Hopkins Hospital
Baltimore, MD 21287
United States

Primary Contact:
Margaret Mensa, RN
Email: mmensa2@jhmi.edu
Phone: 410 614 1608
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.